This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Gonadotropin-Releasing Hormone (GnRH)-Antagonist Therapy in Rheumatoid Arthritis (AGRA)

This study has been completed.
Norwegian Foundation for Health and Rehabilitation
University of Oslo
Information provided by (Responsible Party):
Anita Kass, Betanien Hospital Identifier:
First received: April 24, 2008
Last updated: August 3, 2012
Last verified: August 2012
The purpose of this study is to compare the safety and efficacy of gonadotropin-releasing hormone (GnRH) antagonist therapy versus placebo in patients with moderate to severe rheumatoid arthritis.

Condition Intervention Phase
Rheumatoid Arthritis Drug: Cetrorelix Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Antagonist to Gonadotropin-Releasing Hormone in Rheumatoid Arthritis (AGRA): A Double-blind, Randomized, Placebo Controlled Trial

Resource links provided by NLM:

Further study details as provided by Anita Kass, Betanien Hospital:

Primary Outcome Measures:
  • Change in Disease Activity Score (DAS28CRP) in cetrorelix group versus placebo group [ Time Frame: From baseline to day 5 ]

Secondary Outcome Measures:
  • Change in DAS28 (CRP/ESR) [ Time Frame: From baseline to day 2/5 /10/15 ]
  • Change in anti-CCP level [ Time Frame: From baseline to day 2/5/10/15 ]
  • Change in cytokine level [ Time Frame: From baseline to day 2/5/10/15 ]
  • Change in ACR core set measures [ Time Frame: From baseline to day 2/5/10/15 ]
  • Proportion of patients with ACR 20/50/70/90 and EULAR good/moderate/none responders [ Time Frame: Baseilne to day 2/5/10/15 ]
  • Adverse events [ Time Frame: Baseline up to day 15 ]
    Number of patients with adverse events (and serious adverse events) up to day 15 in each group

  • Proportion of patients with DAS28low disease activity/remission [ Time Frame: Baseline to day 2/5/10/15 ]
  • Change in HAQ scores [ Time Frame: From baseline to day 5/10/15 ]
  • Correlation between percent changes in hormones, disease activity and biomarkers [ Time Frame: By day 2, 5, 10 and 15 ]
    This endpoint is not directly related to clinical efficacy. Hormones include LH, FSH, oestradiol, testosterone,and cortisol. Biomarkers include immunologic markers, bone markers and cardiovascular markers. This secondary endpoint was sent to authorities during the study before unblinding.

Enrollment: 104
Study Start Date: May 2008
Study Completion Date: October 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Cetrorelix
3-5 mg s.c. on days 1-5
Placebo Comparator: 2
NaCl solution
Drug: Placebo
3-5 ml NaCl s.c. on days 1-5


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult between 18 years and above
  • Moderate to severe disease activity
  • Negative pregnancy test for women of childbearing potential
  • Use of reliable method of contraception (non-hormonal) by sexually active female patients

Exclusion Criteria:

  • Patients who are pregnant or breastfeeding
  • Patients taking biologic therapy or prednisolone >7.5mg
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00667758

Deaprtment of Rheumatology, Betanien Hospital
Skien, Norway
Sponsors and Collaborators
Betanien Hospital
Norwegian Foundation for Health and Rehabilitation
University of Oslo
Principal Investigator: Kåss University of Oslo
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Anita Kass, Dr Anita Kåss, Betanien Hospital Identifier: NCT00667758     History of Changes
Other Study ID Numbers: R1/05
2007/2/0174 ( Other Grant/Funding Number: Norwegian Foundation for Health and Rehabilitation )
Study First Received: April 24, 2008
Last Updated: August 3, 2012

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Hormone Antagonists processed this record on September 21, 2017